This content is sourced exclusively from TruthTides clinical reference data and does not constitute medical advice.
Clinical Question
What is the current state of clinical evidence regarding the use of Melanotan II and Cartalax for skin health, pigmentation, and aging-related markers?
Evidence Snapshot
- Melanotan II: Grade C evidence. Non-selective melanocortin receptor agonist. Confirmed tanning effects with significant regulatory safety warnings.
- Cartalax: Grade C (borderline C/D). Tripeptide (Ala-Glu-Asp) studied primarily in preclinical aging models and one small human patent-embedded study.
What the Research Shows
Melanotan II Evidence confirms that Melanotan II functions as a potent stimulator of melanogenesis, resulting in skin darkening. Research identifies it as a non-selective agonist acting on melanocortin receptors MC1R through MC5R. While the tanning effect is validated, the non-selective nature of the compound leads to systemic effects beyond the skin. Clinical concerns have been raised regarding its potential for melanoma promotion. Due to these factors, both the FDA and the TGA have issued formal safety communications regarding its use.
Cartalax Research into Cartalax (also known as the AED peptide) involves its role in cellular aging and tissue metabolism. Preclinical models have examined its impact on skin aging and kidney aging. In rat and mesenchymal stem cell (MSC) models, the peptide demonstrated a 1.4 to 2.1-fold increase in chondrocyte proliferation at concentrations of 200 ng/mL.
Human data for Cartalax is highly limited, originating from a single study embedded in a patent (RU2299741C1) by the St. Petersburg Institute of Bioregulation and Gerontology. This study involved 29 patients with knee osteoarthritis rather than primary skin concerns, though the peptide is frequently cited in the context of aging-related nephroprotection and skin models in preclinical settings. In the human cohort, improvements in pain and mobility were reported by 54.5% to 62.7% of participants, though no radiographic changes were observed.
Mechanism
Melanotan II The mechanism of action for Melanotan II involves the activation of the MC1R receptor to stimulate melanin production. However, it also activates MC3R and MC4R, which are associated with appetite regulation and sexual function, and MC5R, which is located in the sebaceous glands.
Cartalax Cartalax is a tripeptide (H-Ala-Glu-Asp-OH) with a molecular weight of 333.29 g/mol. It is proposed to modulate the expression of genes associated with aging and tissue structure. Specifically, it has been shown to influence SIRT1, SIRT6, Ki-67, and p53 markers. In cartilage and connective tissue models, it targets SOX9, aggrecan, type II collagen, and COMP to normalize metabolism.
Limitations of the Evidence
The evidence for these compounds is characterized by significant gaps:
- Melanotan II: The primary limitation is non-selective receptor activation, which results in off-target effects across multiple organ systems. There is a lack of long-term safety data, particularly concerning its impact on melanocytic lesions.
- Cartalax: The human evidence is considered low-confidence (Grade C/D) because it rests entirely on an unregistered patent narrative. There are no Phase III clinical trials, no registered trial data in public databases, and internal inconsistencies exist regarding dose rationale in the primary patent source. It is not approved by the FDA or EMA.
Clinical Takeaway
Melanotan II demonstrates clear efficacy for skin pigmentation but is categorized by significant safety concerns and regulatory warnings due to its non-selective mechanism. Cartalax shows potential in preclinical aging models, but human clinical evidence remains insufficient to confirm efficacy or safety for anti-aging applications. Physicians should note that Melanotan II has received formal safety warnings from the FDA and TGA, while Cartalax is currently sold in Russia as a dietary supplement and lacks Western regulatory approval.
Clinicians looking for more information on available research may search for peptide therapy near me to connect with specialized providers. To locate a qualified professional, you can also use our tool to find a doctor.
Sources
- Melanotan II: University of Arizona development records; FDA and TGA Safety Communications.
- Cartalax: Patent RU2299741C1 / WO2007139433A1 / EA010574B1; St. Petersburg Institute of Bioregulation and Gerontology clinical data; Russian dietary supplement certification RU.77.99.88.003.R.004070.11.22.
Referenced Peptides
This content was generated from TruthTides clinical reference data. It does not constitute medical advice. Always consult a qualified healthcare provider.